Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STREAM-VCI: Symptomatic Treatment of Vascular Cognitive Impairment
NCT02098824Phase 3Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2014
- Primary completion
- Dec 2016
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of galantamine and methylphenidate hydrochloride extended-release chewable tablet in vascular cognitive impairment (VCI) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Change on performance on executive function at 3.5 hours and Change on performance on memory at 3.5 hours. Status: unknown.
02
Drugs
galantaminemethylphenidate hydrochloride extended-release chewable tablet
03
Conditions
vascular cognitive impairment (VCI)
Beyond the preview
Go deeper on NCT02098824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098824.